This Article Full Text Full Text (PDF) All Versions of this Article: 90/10/5663    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Landriscina, M. Articles by Cignarelli, M. Search for Related Content PubMed PubMed Citation Articles by Landriscina, M. Articles by Cignarelli, M. Related Collections Thyroid Endocrine Oncology

Reverse Transcriptase Inhibitors Down-Regulate Cell Proliferation in Vitro and in Vivo and Restore Thyrotropin Signaling and Iodine Uptake in Human Thyroid Anaplastic Carcinoma

Dipartimento di Scienze Mediche e del Lavoro, Cattedra di Oncologia Medica (M.L., S.A., A.P.), Dipartimento di Scienze Mediche e del Lavoro, Cattedra di Endocrinologia (A.F., M.C.), Centro di Medicina Molecolare (M.L., A.F., S.A., A.P., M.C.), Università degli Studi di Foggia, Foggia, Italia; Istituto di Medicina Interna, Cattedra di Oncologia Medica (C.Bag., A.C., C.Bar.), Università Cattolica del S. Cuore, Roma, Italia; Istituto Superiore di Sanità (C.S.), Roma, Italia; and Dipartimento delle Emergenze e dei Trapianti d’Organo, Cattedra di Endocrinologia (F.G.), Università di Bari, Bari, Italia

Address all correspondence to: Dr. Matteo Landriscina, Cattedra di Oncologia Medica, Università degli Studi di Foggia, Viale Pinto, 1-71100 Foggia, Italy. E-mail: m.landriscina{at}unifg.it.

Context: Two classes of repeated genomic elements, retrotransposons and endogenous retroviruses, encode for endogenous nontelomeric reverse transcriptase (RT), a gene that is down-regulated in differentiated cells but is highly expressed in embryonic and transformed tissues. Two nonnucleosidic RT inhibitors, efavirenz and nevirapine, currently used in HIV treatment, reversibly down-regulate tumor growth and induce differentiation in several human tumor cell models.

Objectives: Aggressive biological behavior and loss of specific thyroid cell functions, such as thyroglobulin, thyroid peroxidase, TSH receptor, Na/I symporter expression, and iodine uptake are features of anaplastic thyroid cancer. Thus, we evaluated the use of RT inhibitors as a potentially differentiating and molecular-targeted treatment of this neoplasm.

Results: Our findings showed that nevirapine and efavirenz reversibly inhibit cell proliferation without triggering cell death in the undifferentiated thyroid carcinoma ARO and FRO cells, which exhibited high levels of endogenous RT activity. Inhibition of cell growth was correlated with accumulation of cells in the G₀/G₁ phase of the cell cycle, with a concomitant decrease in the S phase. Moreover, treated cells demonstrated a differentiated phenotype and a significant reprogramming of gene expression characterized by up-regulation of the TSH receptor, thyroglobulin, thyroid peroxidase, and Na/I symporter genes. Interestingly, RT inhibition reestablished the ability to uptake iodine in response to TSH either in vitro or in vivo and reversibly down-regulated tumor growth in mice xenografts of ARO cells.

Conclusions: These findings support the need for clinical trials to clarify whether RT inhibitors may restore the sensitivity to radiometabolic therapy in anaplastic thyroid tumors.

This article has been cited by other articles:

				G. Brabant Thyrotropin Suppressive Therapy in Thyroid Carcinoma: What Are the Targets? J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1167 - 1169. [Full Text] [PDF]

				C. S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K. B. Ain, and N. Mitsiades Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4013 - 4021. [Abstract] [Full Text] [PDF]